<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004373</url>
  </required_header>
  <id_info>
    <org_study_id>199/11960</org_study_id>
    <secondary_id>UTHSC-92120</secondary_id>
    <nct_id>NCT00004373</nct_id>
  </id_info>
  <brief_title>Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether the benzodiazepine alprazolam reinforces self-medication&#xD;
      behavior in anxious patients with varying histories of using other drugs.&#xD;
&#xD;
      II. Establish outpatient methods for the study of self-medication and drug reinforcement in&#xD;
      patients vulnerable to prescription drug abuse or dependence.&#xD;
&#xD;
      III. Evaluate the influence of alcohol and other non-prescription drug use as determinants of&#xD;
      vulnerability in these patients.&#xD;
&#xD;
      IV. Identify personality, attitudinal, or other variables that might predict different&#xD;
      patterns of self-medication.&#xD;
&#xD;
      V. Assess the effects of cognitive-behavioral therapy on alprazolam self-medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This protocol involves different experiments examining self-medication with&#xD;
      anxiolytic medications in selected patients, and cognitive-behavioral therapy for anxiety.&#xD;
      Capsules are color coded and taken under double-blind conditions. Compliance is monitored&#xD;
      with the Medication Event Monitoring System, which automatically registers the date and time&#xD;
      each bottle is opened.&#xD;
&#xD;
      The physician directs therapy administration, using some combination of the following: blind&#xD;
      choice test, antianxiety agent(s), placebo, and cognitive-behavioral therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <completion_date>March 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>Anxiety Disorder</condition>
  <condition>Panic Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Primary diagnosis of generalized anxiety or panic disorder Determined by Structured&#xD;
             Clinical Interview for DSM IV&#xD;
&#xD;
          -  Hamilton Anxiety Scale (HAM-A) score at least 14 AND Profile of Mood States (POMS)&#xD;
             tension/anxiety scale score at least 20&#xD;
&#xD;
          -  Concurrent diagnoses allowed: Mild to moderate agoraphobia Simple or social phobias&#xD;
             Secondary unipolar affective disorders&#xD;
&#xD;
          -  No current substance abuse, dependence, or substance abuse treatment Drug-free urine&#xD;
             sample required&#xD;
&#xD;
          -  No history of other primary Axis I diagnosis other than tobacco dependence&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  No prior formalized non-drug therapy for anxiety disorder&#xD;
&#xD;
          -  No concurrent prescription psychoactive medication&#xD;
&#xD;
          -  No history of benzodiazepine dependence&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 to 50&#xD;
&#xD;
          -  Other: Medically healthy Negative pregnancy test required No occupational requirement&#xD;
             to work in hazardous situations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Roache</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Roache JD, Stanley MA, Creson DR, Shah NN, Meisch RA. Alprazolam-reinforced medication use in outpatients with anxiety. Drug Alcohol Depend. 1997 May 2;45(3):143-55. doi: 10.1016/s0376-8716(97)01354-9.</citation>
    <PMID>9179516</PMID>
  </reference>
  <reference>
    <citation>Roache JD, Stanley MA: Diazepam reinforcement in anxious patients. Experimental and Clinical Psychopharmacology 4(3): 308-314, 1996.</citation>
  </reference>
  <verification_date>May 2003</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>anxiety disorder</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>panic disorder</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

